Cynata Therapeutics is a regenerative medicine company, listed on the Australian exchange with the ticker symbol CYP (ASX: CYP). The company recently broke onto the regenerative medicine scene by developing Cymerus™, a therapeutic stem cell platform technology that utilizes discoveries made at the University of Wisconsin-Madison (UWM).
UWM is a world-renowned leader in stem cell research that is best known for the work by Professor James Thomson’s research team, which succeeded in first isolating human embryonic stem cells (hESCs) in 1998 and successfully producing induced pluripotent stem cells (iPSCs) from human adult cells in 2007.
Cynata co-founder, Professor Igor Slukvin, was a member of the team that conducted UWM’s pioneering iPSC research. UWM is also infamous for its strong patent positions pertaining to the process of human embryonic stem cell (hESC) derivation.
Economic Manufacture of MSCs on a Commercial Scale is Limiting Factor to Therapeutic Use
In a world first, Cynata is using its proprietary Cymerus™ technology to address the main bottleneck limiting therapeutic use of mesenchymal stem cells (MSCs), which is that existing methods for the production of MSCs do not achieve economic manufacture of the cells at commercial scale. This opens up a wide range of therapeutic and manufacturing possibilities for Cynata Therapeutics.
In the video below, Cynata Managing Director and CEO, Dr. Ross MacDonald discusses the Cymerus™ technology, including how it will make the process of mesechymal stem cell (MSC) manufacturing scalable, reproducible, and economical. Interestingly, the process only requires a single donor to provide the source tissue for the MSC manufacturing, a pretty incredible feat. Dr. MacDonald also discusses the commercial benefits of the technology and how the manufacturing platform will position the company for future success within the marketplace.
